Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern

B. Kovacech, L. Fialova, P. Filipcik, R. Skrabana, M. Zilkova, N. Paulenka-Ivanovova, A. Kovac, D. Palova, GP. Rolkova, K. Tomkova, NT. Csokova, K. Markova, M. Skrabanova, K. Sinska, N. Basheer, P. Majerova, J. Hanes, V. Parrak, M. Prcina, O....

. 2022 ; 76 (-) : 103818. [pub] 20220122

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011119

BACKGROUND: The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S protein raised concern about activity of current vaccines and therapeutic antibodies. Independent studies have shown that mutant variants are partially or completely resistant against some of the therapeutic antibodies authorized for emergency use. METHODS: We employed hybridoma technology, ELISA-based and cell-based S-ACE2 interaction assays combined with authentic virus neutralization assays to develop second-generation antibodies, which were specifically selected for their ability to neutralize the new variants of SARS-CoV-2. FINDINGS: AX290 and AX677, two monoclonal antibodies with non-overlapping epitopes, exhibit subnanomolar or nanomolar affinities to the receptor binding domain of the viral Spike protein carrying amino acid substitutions N501Y, N439K, E484K, K417N, and a combination N501Y/E484K/K417N found in the circulating virus variants. The antibodies showed excellent neutralization of an authentic SARS-CoV-2 virus representing strains circulating in Europe in spring 2020 and also the variants of concern B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617.2 (Delta). In addition, AX677 is able to bind Omicron Spike protein just like the wild type Spike. The combination of the two antibodies prevented the appearance of escape mutations of the authentic SARS-CoV-2 virus. Prophylactic administration of AX290 and AX677, either individually or in combination, effectively reduced viral burden and inflammation in the lungs, and prevented disease in a mouse model of SARS-CoV-2 infection. INTERPRETATION: The virus-neutralizing properties were fully reproduced in chimeric mouse-human versions of the antibodies, which may represent a promising tool for COVID-19 therapy. FUNDING: The study was funded by AXON Neuroscience SE and AXON COVIDAX a.s.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011119
003      
CZ-PrNML
005      
20230815105631.0
007      
ta
008      
220425s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ebiom.2022.103818 $2 doi
035    __
$a (PubMed)35078012
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Kovacech, Branislav $u AXON COVIDAX a. s.; Bratislava, 811 02, Slovakia; AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia. Electronic address: kovacech@axon-neuroscience.eu
245    10
$a Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern / $c B. Kovacech, L. Fialova, P. Filipcik, R. Skrabana, M. Zilkova, N. Paulenka-Ivanovova, A. Kovac, D. Palova, GP. Rolkova, K. Tomkova, NT. Csokova, K. Markova, M. Skrabanova, K. Sinska, N. Basheer, P. Majerova, J. Hanes, V. Parrak, M. Prcina, O. Cehlar, M. Cente, J. Piestansky, M. Fresser, M. Novak, M. Slavikova, K. Borsova, V. Cabanova, B. Brejova, T. Vinař, J. Nosek, B. Klempa, L. Eyer, V. Hönig, M. Palus, D. Ruzek, T. Vyhlidalova, P. Strakova, B. Mrazkova, D. Zudova, G. Koubkova, V. Novosadova, J. Prochazka, R. Sedlacek, N. Zilka, E. Kontsekova
520    9_
$a BACKGROUND: The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S protein raised concern about activity of current vaccines and therapeutic antibodies. Independent studies have shown that mutant variants are partially or completely resistant against some of the therapeutic antibodies authorized for emergency use. METHODS: We employed hybridoma technology, ELISA-based and cell-based S-ACE2 interaction assays combined with authentic virus neutralization assays to develop second-generation antibodies, which were specifically selected for their ability to neutralize the new variants of SARS-CoV-2. FINDINGS: AX290 and AX677, two monoclonal antibodies with non-overlapping epitopes, exhibit subnanomolar or nanomolar affinities to the receptor binding domain of the viral Spike protein carrying amino acid substitutions N501Y, N439K, E484K, K417N, and a combination N501Y/E484K/K417N found in the circulating virus variants. The antibodies showed excellent neutralization of an authentic SARS-CoV-2 virus representing strains circulating in Europe in spring 2020 and also the variants of concern B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617.2 (Delta). In addition, AX677 is able to bind Omicron Spike protein just like the wild type Spike. The combination of the two antibodies prevented the appearance of escape mutations of the authentic SARS-CoV-2 virus. Prophylactic administration of AX290 and AX677, either individually or in combination, effectively reduced viral burden and inflammation in the lungs, and prevented disease in a mouse model of SARS-CoV-2 infection. INTERPRETATION: The virus-neutralizing properties were fully reproduced in chimeric mouse-human versions of the antibodies, which may represent a promising tool for COVID-19 therapy. FUNDING: The study was funded by AXON Neuroscience SE and AXON COVIDAX a.s.
650    _2
$a angiotensin-konvertující enzym 2 $x chemie $x genetika $x metabolismus $7 D000085962
650    _2
$a zvířata $7 D000818
650    _2
$a monoklonální protilátky $x imunologie $x terapeutické užití $7 D000911
650    _2
$a antigenní drift a shift $7 D000088603
650    _2
$a protinádorové látky imunologicky aktivní $x imunologie $x terapeutické užití $7 D000074322
650    _2
$a COVID-19 $x virologie $7 D000086382
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a lidé $7 D006801
650    _2
$a imunodominantní epitopy $x imunologie $7 D016056
650    _2
$a kinetika $7 D007700
650    _2
$a plíce $x patologie $7 D008168
650    _2
$a myši $7 D051379
650    _2
$a mutace $7 D009154
650    _2
$a neutralizační testy $7 D009500
650    _2
$a vazba proteinů $7 D011485
650    _2
$a SARS-CoV-2 $x genetika $x imunologie $x izolace a purifikace $7 D000086402
650    _2
$a glykoprotein S, koronavirus $x genetika $x imunologie $x metabolismus $7 D064370
650    _2
$a farmakoterapie COVID-19 $7 D000093485
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fialova, Lubica $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Filipcik, Peter $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia; Institute of Neuroimmunology, Slovak Academy of Sciences; Bratislava, 845 10, Slovakia
700    1_
$a Skrabana, Rostislav $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Zilkova, Monika $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Paulenka-Ivanovova, Natalia $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Kovac, Andrej $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Palova, Denisa $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Rolkova, Gabriela Paulikova $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Tomkova, Katarina $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Csokova, Natalia Turic $u Institute of Neuroimmunology, Slovak Academy of Sciences; Bratislava, 845 10, Slovakia
700    1_
$a Markova, Karina $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Skrabanova, Michaela $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia; Institute of Neuroimmunology, Slovak Academy of Sciences; Bratislava, 845 10, Slovakia
700    1_
$a Sinska, Kristina $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Basheer, Neha $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Majerova, Petra $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Hanes, Jozef $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia; Institute of Neuroimmunology, Slovak Academy of Sciences; Bratislava, 845 10, Slovakia
700    1_
$a Parrak, Vojtech $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Prcina, Michal $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Cehlar, Ondrej $u Institute of Neuroimmunology, Slovak Academy of Sciences; Bratislava, 845 10, Slovakia
700    1_
$a Cente, Martin $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia; Institute of Neuroimmunology, Slovak Academy of Sciences; Bratislava, 845 10, Slovakia
700    1_
$a Piestansky, Juraj $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Fresser, Michal $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia
700    1_
$a Novak, Michal $u AXON NEUROSCIENCE SE; Larnaca, 6016, Cyprus
700    1_
$a Slavikova, Monika $u Biomedical Research Center, Institute of Virology, Slovak Academy of Sciences; Bratislava, 845 05, Slovakia
700    1_
$a Borsova, Kristina $u Biomedical Research Center, Institute of Virology, Slovak Academy of Sciences; Bratislava, 845 05, Slovakia; Department of Microbiology and Virology, Faculty of Natural Sciences, Comenius University in Bratislava; Bratislava, 842 15, Slovakia
700    1_
$a Cabanova, Viktoria $u Biomedical Research Center, Institute of Virology, Slovak Academy of Sciences; Bratislava, 845 05, Slovakia
700    1_
$a Brejova, Bronislava $u Department of Computer Science, Faculty of Mathematics, Physics and Informatics, Comenius University in Bratislava; Bratislava, 842 48, Slovakia
700    1_
$a Vinař, Tomas $u Department of Applied Informatics, Faculty of Mathematics, Physics and Informatics, Comenius University in Bratislava; Bratislava, 842 48, Slovakia
700    1_
$a Nosek, Jozef $u Department of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava; Bratislava, 842 15, Slovakia
700    1_
$a Klempa, Boris $u Biomedical Research Center, Institute of Virology, Slovak Academy of Sciences; Bratislava, 845 05, Slovakia
700    1_
$a Eyer, Luděk $7 xx0098551 $u Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ-37005 Ceske Budejovice, Czech Republic; Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic
700    1_
$a Hönig, Václav, $d 1982- $u Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ-37005 Ceske Budejovice, Czech Republic; Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic $7 jcu2012681186
700    1_
$a Palus, Martin $u Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ-37005 Ceske Budejovice, Czech Republic; Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic
700    1_
$a Růžek, Daniel, $d 1981- $u Biomedical Research Center, Institute of Virology, Slovak Academy of Sciences; Bratislava, 845 05, Slovakia $7 stk2008441707
700    1_
$a Vyhlidalova, Tereza $u Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ-37005 Ceske Budejovice, Czech Republic
700    1_
$a Strakova, Petra $u Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ-37005 Ceske Budejovice, Czech Republic; Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic
700    1_
$a Mrazkova, Blanka $u Czech Centre of Phenogenomics, Institute of Molecular Genetics, ASCR v.v.i, Prumyslova 595, 252 50, Vestec, Czech Republic
700    1_
$a Zudova, Dagmar $u Czech Centre of Phenogenomics, Institute of Molecular Genetics, ASCR v.v.i, Prumyslova 595, 252 50, Vestec, Czech Republic
700    1_
$a Koubkova, Gizela $u Czech Centre of Phenogenomics, Institute of Molecular Genetics, ASCR v.v.i, Prumyslova 595, 252 50, Vestec, Czech Republic
700    1_
$a Novosadova, Vendula $u Czech Centre of Phenogenomics, Institute of Molecular Genetics, ASCR v.v.i, Prumyslova 595, 252 50, Vestec, Czech Republic
700    1_
$a Prochazka, Jan $u Czech Centre of Phenogenomics, Institute of Molecular Genetics, ASCR v.v.i, Prumyslova 595, 252 50, Vestec, Czech Republic
700    1_
$a Sedlacek, Radislav $u Czech Centre of Phenogenomics, Institute of Molecular Genetics, ASCR v.v.i, Prumyslova 595, 252 50, Vestec, Czech Republic
700    1_
$a Zilka, Norbert $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia; Institute of Neuroimmunology, Slovak Academy of Sciences; Bratislava, 845 10, Slovakia. Electronic address: zilka@axon-neuroscience.eu
700    1_
$a Kontsekova, Eva $u AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia; Institute of Neuroimmunology, Slovak Academy of Sciences; Bratislava, 845 10, Slovakia
773    0_
$w MED00190061 $t EBioMedicine $x 2352-3964 $g Roč. 76, č. - (2022), s. 103818
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35078012 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20230815105628 $b ABA008
999    __
$a ok $b bmc $g 1788953 $s 1162317
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 76 $c - $d 103818 $e 20220122 $i 2352-3964 $m EBioMedicine $n EBioMedicine $x MED00190061
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace